ERBB2 and neoplasm: Remarkably, more than 20 years later, little is known about the dynamics of NK cell function in the TME of BC patients undergoing anti-HER2 blockade treatment, other than trastuzumab-based regimens induce an increase in the proportion of NK cells infiltrating the tumor mass (35).